# A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma

> **NCT04003896** · PHASE2 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04003896
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-24
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The manufacturer and funder Eli Lilly requested to terminate the study
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003896, "A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04003896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*